Bupa Arabia Cooperative Insurance has entered a landmark partnership with Thmanyah, a subsidiary of Saudi Research and Media Group (SRMG), one of the Kingdom's foremost media and content platforms, to sponsor coverage of the Saudi Pro League during the 2025 and 2026 seasons, strengthening its connection with the nation's football enthusiasts.
The alliance reflects Bupa Arabia's vision of weaving healthcare and well-being into the fabric of daily life by reaching millions of football fans across the Kingdom's most passionate sporting community. It also supports Vision 2030's objective of promoting healthier, more active lifestyles throughout the nation.
"Football is the heartbeat of Saudi Arabia, and we are proud to connect healthcare with this passion. Through our partnership with Thmanyah, we aim to inspire healthier lifestyles while being part of the moments that bring fans together. This initiative also extends our CareConnect platform, bringing health and wellness closer to fans both on and off the field," said Tal Nazer, Bupa Arabia.
The partnership will deliver expansive brand presence, with over 2,500 exposures across 306 matches, complemented by hundreds of studio and feature programme episodes. Using sophisticated demographic targeting combined with AI-driven performance analytics, each campaign will be crafted to achieve optimal reach, relevance, and engagement.
By entering the football domain through a trusted media platform, Bupa Arabia builds on its "Care Beyond Walls" pledge, further expanding the CareConnect platform and bridging the thrill of sport with healthcare awareness, ensuring fans remain connected to wellness wherever they follow the game.
source:newsreleases.co.uk
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Kye Pharmaceuticals' AGAMREE (vamorolone) approved in Canada to treat DMD
XenoSTART and Minerva Imaging expand partnership
Pharming receives FDA priority review for leniolisib in children with APDS
Abbvie invests in US expansion
Ocular Therapeutix prices USD475m common stock offering
Orion's ODM-105 (tasipimidine) insomnia study fails to achieve primary goal
Merck's WINREVAIR reduces clinical worsening by 76% in early PAH patients
Vicore Pharma's buloxibutid receives orphan drug designation in Japan